Weekly treatment with Context Therapeutics’ CTIM-76 was generally well tolerated and shrank tumors in some people with heavily pretreated platinum-resistant ovarian cancer, according…
Gynecological cancer
Cellxlife signed a licensing agreement for a cell-based vaccine from Mayo Clinic that aims to teach the body’s immune system to recognize and…
SIM0505, a treatment being developed by Nextcure and Simcere Zaiming, resulted in partial responses in more than half of patients with hard- to-treat…
A combination of the immune-modulating treatments Lymphir (denileukin diftitox) and Keytruda (pembrolizumab) led to clinical benefit in nearly half of evaluable patients in an exploratory clinical…
The experimental cancer vaccine Tedopi (OSE2101), when given in combination with the approved injection therapy Keytruda (pembrolizumab), outperforms standard-of-care treatment in delaying disease…
A large clinical trial testing Merck’s therapy candidate sacituzumab tirumotecan (sac-TMT) in people with hard-to-treat endometrial cancer has achieved its main goal, with sac-TMT…
Liraltagene autoleucel (lira-cel), an experimental cell therapy in clinical development for recurrent ovarian cancer, has been tolerated well so far in an early clinical trial,…
May 8 is World Ovarian Cancer Day, a time when advocates around the world raise their voices to increase awareness, support those affected, and…
The U.S. Food and Drug Administration (FDA) has granted fast track status to a combination of lunresertib and zedoresertib — two therapies in development by…
In an early clinical trial, people with certain advanced or treatment-resistant gynecological cancers showed strong responses to the experimental therapy mocertatug rezetecan (Mo-Rez), according…
